p53 (dominant negative R175H mutant)-pcw107-V5 Citations (2)

Originally described in: Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877. PubMed Journal

---

Articles Citing p53 (dominant negative R175H mutant)-pcw107-V5

Articles
ANKLE1 cleaves mitochondrial DNA and contributes to cancer risk by promoting apoptosis resistance and metabolic dysregulation. Przanowski P, Przanowska RK, Guertin MJ. Commun Biol. 2023 Mar 1;6(1):231. doi: 10.1038/s42003-023-04611-w. PubMed
The mTORC2 component SIN1 post-transcriptionally regulates TYMS levels and modulates P53 activity in response to 5-FU chemotherapy. Sayed AE, Gomes N, Zakrzewski M, Liudkovska V, Serwa R, Azzi A. Cell Commun Signal. 2026 Jan 28;24(1):111. doi: 10.1186/s12964-025-02640-y. PubMed

If you have published an article using this material, please email us at to have your article added to this page.